| Literature DB >> 25383081 |
Hee Kyoung Ryu1, Yong-Hyeon Baek1, Yeon-Cheol Park1, Byung-Kwan Seo1.
Abstract
Acupuncture is generally accepted as a safe and harmless treatment option for alleviating pain. To explore the pain mechanism, numerous animal models have been developed to simulate specific human pain conditions, including cancer-induced bone pain (CIBP). In this study, we analyzed the current research methodology of acupuncture for the treatment of CIBP. We electronically searched the PubMed database for animal studies published from 2000 onward using these search terms: (bone cancer OR cancer) AND (pain OR analgesia) AND (acupuncture OR pharmacopuncture OR bee venom). We selected articles that described cancer pain in animal models. We analyzed the methods used to induce cancer pain and the outcome measures used to assess the effects of acupuncture on CIBP in animal models. We reviewed articles that met our inclusion criteria. Injection of mammary cancer cells into the cavity of the tibia was the most frequently used method for inducing CIBP in the animal models. Among the eight selected studies, five studies demonstrated the effects of electroacupuncture on CIBP. The effects of acupuncture were assessed by measuring pain-related behavior. Future researches will be needed to ascertain the effectiveness of acupuncture for treating CIBP and to explore the specific mechanism of CIBP in animal models.Entities:
Year: 2014 PMID: 25383081 PMCID: PMC4212539 DOI: 10.1155/2014/191347
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow diagram of the study selection process.
Models of cancer pain.
| Animal | Cell line | Tumor type | Strain | Sex | Injection site | Reference |
|---|---|---|---|---|---|---|
| Rat | Walker 256 | Mammary gland carcinoma | Wistar | Female | Tibia | [ |
| Sprague-Dawley | Female | Tibia | [ | |||
| AT-3.1 | Prostate carcinoma | Copenhagen | Female | Tibia | [ | |
|
| ||||||
| Mouse | S-180 | Sarcoma | BALB/c | Male | Femur | [ |
Interventions and outcomes.
| Reference | Intervention | Number of animals | Acupoint | Stimulation | Control | Number of animals | Days of EA treatmenta | Outcome measure | Assessment daysa | Outcome | Significance |
|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | EA | 12 | ST-36 | 4 Hz 2.5 s/100 Hz 5 s, | Cancer only | 12 | Days 4~end of the study | Von Frey filament test (g) | 10, 16, 22, 27 | Increased |
|
|
| |||||||||||
| [ | EA + Celebrex | 12 | ST-36 | 4 Hz 2.5 s/100 Hz 5 s, | Celebrex 5 mg/(kg∗g) | 12 | Days 4~end of the study | Von Frey filament test (g) | 10, 16, 22, 27 | Increased |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | PWLb (sec) | 12, 15, 18 | Increased Day 15 (9.18 ± 0.64 s) and Day 18 (9.19 ± 0.40 s) |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | IL-1 | After behavioral test | Inhibited |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | PWPTc (g) | 12, 14, 17 | Increased |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | PWLb (sec) | 12, 15, 18 | Increased |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | PPD mRNA (Spinal cord) | After behavioral test | Inhibited |
|
|
| |||||||||||
| [ | EA | 7 | GB-30 | 10 Hz, 2 mA, 0.4 ms, 30 min | Sham EA | 7 | Days 14–18 | Dynorphin | After behavioral test | Inhibited | — |
|
| |||||||||||
| [ | EA + morphined | each 10 | EX-B2 | 2 Hz/100 Hz, 30 min | Cancer only | 10 | Days 15–20 | PWLb (sec) | 18, 20 | Increased |
|
|
| |||||||||||
| [ | EA + morphined | each 10 | EX-B2 | 2 Hz/100 Hz, 30 min | Cancer only | 10 | Days 15–20 | GFAP | After behavioral test | Inhibited |
|
|
| |||||||||||
| [ | EA | 8 | ST-36 | 2 Hz, 0.3 ms, <1 mA, 30 min | Cancer only | 8 | Days 1–9 | Von Frey filament test (g) | 1, 3, 5, 7, 9 | Increased |
|
|
| |||||||||||
| [ | EA | 8 | ST-36 | 2 Hz, 0.3 ms, <1 mA, 30 min | Cancer only | 8 | Days 1–9 | Cumulative lifting duratione (sec) | 3, 5, 7, 9 | Increased |
|
|
| |||||||||||
| [ | EA | 8 | ST-36 | 2 Hz, 0.3 ms, <1 mA, 30 min | Cancer only | 8 | Days 1–9 | Substance P | After behavioral test | Decreased |
|
|
| |||||||||||
| [ | EA | 8 | ST-36 | 2 Hz, 0.3 ms, <1 mA, 30 min | Cancer only | 8 | Days 1–9 |
| After behavioral test | Increased |
|
EA, electroacupuncture; ST-36, Zusanli; BL-60, Kunlun; GB-30, Huantiao; EX-B2, Jiaji; IL-, interleukin-; PPD, preprodynorphin; GFAP, glial fibrillary acidic protein.
aDays after inoculation.
bPWL, Paw withdrawal latency (thermal sensitivity to radiant heat).
cPWPT, Paw withdrawal pressure threshold measured with a Paw Pressure Analgesia Instrument (UgoBasile, Italy).
dElectric current intensity of EA, 2 mA, 1 mA; dose of morphine, 0 mg/(kg∗d), 2.5 mg/(kg∗d), 5 mg/(kg∗d).
eCumulative lifting duration: After approximately 1 h acclimatizationin a clear plastic chamber with wire grid floors at room temperature, the cumulative duration of hind paw-lifting of each mouse was analyzed for 10 min.
Outcome measures.
| Reference | Behavior | Macroscopicfeatures | Histological and biochemical measures (site) | ||
|---|---|---|---|---|---|
| Mechanical stimulus evoked | Heat stimulus evoked | Movement related | |||
| [ | Hind paw withdrawal (von Frey filaments) | Bone surface | |||
|
| |||||
| [ | Paw withdrawal latency (thermal sensitivity to radiant heat) | IL-1 | |||
|
| |||||
| [ | Hind paw withdrawal pressure threshold (PWPT) | Paw withdrawal latency (thermal sensitivity to radiant heat) | PPD mRNA, Dynorphin | ||
|
| |||||
| [ | Paw withdrawal latency (thermal sensitivity to radiant heat) | Bone surface | GFAP | ||
|
| |||||
| [ | Hind paw withdrawal (von Frey filaments) | Cumulative lifting duration | Clear lifting and flinching | Tumor size and volume (MRI scanning) | Substance P |
IL-, interleukin-; PPD, preprodynorphin; GFAP, glial fibrillary acidic protein.